Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease

Bibliography

• JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics 2002, CA, USA. Cancer J. Clin. (2002) 52:23–47.
   PubMed Web of Science ®Google Scholar
• PARKIN DM, BRAY F, FERLAY J, PISANI P: Estimating the world cancer burden: GLOBO CAN 2000. Int. J. Cancer (2001) 94:153–156.
   PubMed Web of Science ®Google Scholar
• POUND CR, PARTIN AW, EISENBERGER MA, CHAN DW, PEARSON JD, WALSH PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 281:1591–1597.
   PubMed Web of Science ®Google Scholar
• JACOBS SC: Spread of prostate cancer to bone. Urology (1983) 21:337.
   PubMed Web of Science ®Google Scholar
• CARLIN BI, ANDRIOLE G: The natural history, skeletal complications, andmanagement of bone metastases in patients with prostate carcinoma. Cancer (2000) 88\(Suppl. 12):52989–52994.
   Google Scholar
• PATAKI A, MULLER K, GREEN JR, MA YF, LI QN, JEE WSS: Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during and after treatment. Anat. Rec. (1997) 249: 458–468.
   PubMedGoogle Scholar
• ROODMAN GD: Biology of osteoclast activation in cancer. J. Clin. Oricol. (2001) 19:3562–3571.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the molecularmechanism responsible for osteodast activation. It provides important background information for the rationale for bisphosphonate therapy.
   Google Scholar
• LIPTON A, COSTA L, ALT S, DEMERS L: Use of markers of bone turnover for monitoring bone metastases and the response to therapy. &min. arca. (2001) 28:54–59.
   Google Scholar
• ••An excellent reference on the evolving roleof bone resorption markers.
   Google Scholar
• SAHARABUDHE C, MAURER C, HASSETT R etal.: Effect of androgen-ablation on bone resorption in men with prostate cancer. Proc. Amer. Soc. Gin arca (2001) 20:184a (Abstract 734).
   Google Scholar
• GARNERO P, BUCHS N, ZEKRI J et al.: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer (2000) 4:858–864.
   Google Scholar
• GREEN JR, ROGERS MJ: Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev. Res. (2002) 55:210–224.
   Web of Science ®Google Scholar
• ••An excellent review on the current status ofbisphosphonate predinical research.
   Google Scholar
• BERRUTI A, DOGLIOTTI L, TUCCI M et al.: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. j. Ural. (2001) 166:2023–2031.
   PubMed Web of Science ®Google Scholar
• •This comprehensive review of the pathophysiology of prostate cancer-induced metabolic bone disease provides essential background information for the use of bisphosphonate therapy.
   Google Scholar
• DUNFORD JE, THOMPSON K, COXON FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. ?Pharm. Exp. Ther. (2001) 296:235–242.
   PubMed Web of Science ®Google Scholar
• VIRTANEN SS, VAANANEN HK, HARKONEN PL, LAKKAKORPI PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. (2002) 62:2708–2714.
   PubMed Web of Science ®Google Scholar
• KREMPIEN B, WIPFLER G, MANEGOLD CH et al.: Prevention and therapy of tumor induced osteolysis by pharmacological antiolysis. j. Cancer Res. Clin. Oncol. (1992) 118(Suppl.):R81 (Abstract V4.10.04).
   Google Scholar
• SAAD F, GLEASON DM, MURRAY R et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. j. Natl. Cancer Inst. (2002) 94:1458-1468. ccA very important trial demonstratingdecreased SREs with zoledronic acid in men with hormone-refractory metastatic prostate carcinoma.
   Google Scholar
• BODY J-J: Dosing regimens and main adverse events of bisphosphonates. Sem. Oncol. (2001) 28\(Suppl. 2):49–53.
   Google Scholar
• •This article provides the advantages and disadvantages of different agents based on safety and dosing issues.
   Google Scholar
• LOOKER AC, ORWOLL ES, JOHNSTON CC Jr et al.: Prevalence of low femoral bone density in older US adults from NHANES III. Bone Miner. Res. (1997) 12:1761–1768.
   Google Scholar
• COOPER C, CAMPION G, MELTON LJ et al.: Hip fractures in the elderly: a worldwide projection. Osteopor. Int. (1992) 2:285–289.
   PubMed Web of Science ®Google Scholar
• POOR G, ATKINSON EJ, O'FALLON WM, MELTON LJ 3rd: Determinants of reduced survival following hip fractures in men. Orthop. Relat. Research (1995) 319:260–265.
   PubMed Web of Science ®Google Scholar
• BAILLIE SP, DAVISON CE, JOHNSON FJ, FRANCIS RIVI: Pathogenesis of vertebral crush fractures in men. Age and Ageing (1992) 21:139–141.
   PubMed Web of Science ®Google Scholar
• BILEZIKIAN JP: Osteoporosis in men. Endocrinol. Metab. (1999) 84:3431–3434.
   Google Scholar
• JACKSON JA, KLEEREKOPER M, PARFITT AM, RAO DS, VILLANUEVA AR, FRAME B: Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. Endocnnol. Metab. (1987) 65:53–58.
   PubMed Web of Science ®Google Scholar
• STEPAN JJ, LACHMAN M, ZVERINA J,PACOVSKY V, BAYLINK DJ: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. j. Clin. Endocnnol. Metab. (1989) 69:523–527.
   PubMed Web of Science ®Google Scholar
• COLLINSON MP, TYRRELL CJ, HUTTON C et al.: Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int. (1994) 54:327–328.
   PubMed Web of Science ®Google Scholar
• MCGRATH SA, DIAMOND T: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. j. Ural. (1995) 154:535–536.
   PubMed Web of Science ®Google Scholar
• ROSS RW, SMALL EJ: Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. I Urol. (2002) 167:1952–1956.
   PubMedGoogle Scholar
• SMITH MR: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology (2002) 60:79–85.
   PubMed Web of Science ®Google Scholar
• WEI JT, GROSS M, JAFFE CA et al.: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology (1999) 54:607–611.
   PubMed Web of Science ®Google Scholar
• KIRATLI BJ, SRINIVAS S, PERKASH I, TERRIS MK: Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology (2001) 57:127–132.
   PubMed Web of Science ®Google Scholar
• HIGANO CS, STEPHENS C, NELSON P et al.: Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc. Amer. Soc. CBI]. Oncol. (1999) 18:314a (Abstract 1207).
   Google Scholar
• DANIELL HW: Osteoporosis after orchiectomy for prostate cancer. j. Ural. (1997) 157:439–444.
   PubMed Web of Science ®Google Scholar
• TOWNSEND MF, SANDERS WH, NORTH WAY RO, GRAHAM JR SD: Bone fractures associated with leuteinizig hormone-releasing hormone agonists used in treatment of prostate carcinoma. Cancer (1997) 79:545–550.
   PubMed Web of Science ®Google Scholar
• OEFELEIN MG, RICCHUITI V, CONRAD W et al.: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. j. Urol. (2001) 166:1724–1728.
   PubMed Web of Science ®Google Scholar
• DIAMOND T, CAMPBELL J, BRYANT C, LYNCH W: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer (1998) 83:1561–1266.
   PubMed Web of Science ®Google Scholar
• DIAMOND TH, WINTERS J, SMITH A etal.: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade, a double blind, randomized, placebo-controlled crossover study. Cancer (2001) 92:1444–1450.
   Google Scholar
• ORWOLL E, ETTINGER M, WEISS S et al.: Alendronate for the treatment of osteoporosis in men. N Engl. j. Med. (2000) 343:604–610.
   PubMed Web of Science ®Google Scholar
• REID IR, BROWN JP, BURCKHARDT P etal.: Intravenous zoledronic acid in postmenopausal women with low mineral density. N Engl. j. Med. (2002) 346:653–661.
   Google Scholar
• ••Provides important data on yearly dosing of bisphosphonates for osteoporosis.
   Google Scholar
• MUKHERJEE T, BARAD D, TURK R, FREEMAN R: A randomized placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. Am. j. Oster Cyriecol. (1996) 175:105–109.
   PubMed Web of Science ®Google Scholar
• CLARKE NW, MCCLURE J, GEORGE NJ et al.: The effects of orchiectomy on skeletal metabolism in metastatic prostate cancer. Scalar/. Urol. Nephrol. (1993) 27:475–483.
   PubMed Web of Science ®Google Scholar
• SMITH MR, MCGOVERN FJ, ZIETMAN AL et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl. j. Med. (2001) 345:948–95
   PubMed Web of Science ®Google Scholar
• ••Critical article demonstrating preventionof androgen-induced osteoporosis with bisphosphonates.
   Google Scholar
• SMITH MR, SHASHA D, MANSOUR R etal.: Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Skeletal Complications of Malignancies. 3rd North American Symposium, Meeting Proceedings, Bethesda, MD, USA (2002) C8:25-27 (Abstract).
   Google Scholar
• DANIELL HW, DUNN S, FERGUSON D, LOMAS G, NIAZI Z, STRATTE PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Ural. (2000) 163:181–186.
   PubMed Web of Science ®Google Scholar
• MOYAD MA: Complementary therapies for reducing the risk of osteoporosis in patients receiving leuteinizig hormone-releasing hormone treatmentiorchiecotmy for prostate cancer: a review and assessment of the need for more research. Urology (2002) 59:34–40.
   PubMed Web of Science ®Google Scholar
• BILEZIKIAN JP, PANEL MEMBERS: Optimal calcium intake: statement of the consensus development panel on optimal calcium intake. JAMA (1994) 272:1942–1948.
   PubMedGoogle Scholar
• Dietary references intakes: Food and Nutrition Board, Institute of Medicine, National Research Council, Washington, DC, USA. National Academy Press (1998).
   Google Scholar
• DAWSON-HUGHES B, HARRIS SS, KRALL EA, DALLAL GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N. Engl. J. Med. (1997) 337:670–676.
   PubMed Web of Science ®Google Scholar
• SUZUKI Y, OISHI Y, YAMAZAKI H et al: How to avoid bone loss in patients with prostatic carcinoma receiving long-term LHRH-analogue. j Ural. (2000) 163:159 (Abstract 707).
   Google Scholar
• ERIKSSON S, ERIKSSON A, STEGE R, CARLSTROM K: Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif Tissue Int. (1995) 57:97–99.
   PubMed Web of Science ®Google Scholar
• CARLSTROM K, STEGE R, HENRIKSSON P, GRANDE M, GUNNARSSON PO, POUSETTE A: Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate (1997) 31:193–197.
   PubMed Web of Science ®Google Scholar
• IVERSON P, TYRRELL CJ, KAISARY AV etal.: Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow-up. J. Ural. (2000) 164:1579–1582.
   Google Scholar
• BOCCARDO F, BARICHELLO M, BATTAGLIA M etal.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur. Ural. (2002) 42:481–490.
   Google Scholar
• ABRAHAMSSON PA: Treatment of locally advanced prostate cancer: a new role for antiandrogen monotherapy? Eur. Ural. (2001) 39:22–28.
   Google Scholar
• IGLESIAS CP, TORGERSON DJ, BEARNE A, BOSE U: The cost utility of bisphosphonate treatment in established osteoporosis. WM(2002) 95:305–311.
   Google Scholar
• CHRISCHILLES EA, DASBACH EJ, RUBENSTEIN LM, COOK JR, TABOUR HK, BLACK DM: The effect of aledronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Fracture Intervention Trial Research Group. Osteoporos. Int. (2001) 12:654–660.
   PubMed Web of Science ®Google Scholar
• DESHARNAIS CASTEL L, BAJWA K, MARKLE JP, TIMBIE JW, ZACKER C, SCHULMAN KA: A microcosting analysis of zoledronic acid and pamidronate therapy with metastatic bone disease. Support. Care Cancer (2001) 9:545–551.
   PubMed Web of Science ®Google Scholar
• BERRUTI A, DOGLIOTTI L, BITOSSI R et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Ural. (2000) 164:1248–1253.
   PubMed Web of Science ®Google Scholar
• ROBS ON M, DAWSON N: How is androgen dependent metastatic prostate cancer best treated? HematolOncol N Am. (1996) 10:727–747.
   Google Scholar
• OFELEIN MG, RICCHIUTI V, CORAD W, RESNICK MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Ural. (2002) 168:1005–1007.
   PubMed Web of Science ®Google Scholar
• CHEN TC: Prostate cancer and spinal cord compression. Oncology (Huntingt) (2001) 15:841–855.
   PubMed Web of Science ®Google Scholar
• SMITH JA, SOLOWAY MS, YOUNG MJ eta].: Complications of advanced prostate cancer. Urology (1999) 54:8–14.
   Google Scholar
• DEMERS LM, COSTA L, LIPTON A eta].: Biochemical markers and skeletal metastases. Cancer (2000) 88:2919–2926.
   Google Scholar
• GARNERO P: Markers of bone turnover inprostate cancer. Cancer Treat. Rev (2001) 3:187–192.
   Google Scholar
• ••A comprehensive review of markers of bone turnover, which will have increased use in monitoring the effectiveness of bisphosphonate therapy.
   Google Scholar
• HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl. J. Med. (1996) 335:1785–1791.
   PubMed Web of Science ®Google Scholar
• •A landmark article demonstrating reduction of skeletal morbidity with pamidronate in breast cancer.
   Google Scholar
• THERIAULT RL, LIPTON A, HORTOBAGYI GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized placebo-controlled trial. J. Clin. Oncol (1999) 17:846–854.
   PubMed Web of Science ®Google Scholar
• LIPTON A, THERIAULT RL, HORTOBAGYI GN et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer (2000) 88:1082–1090.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, GORDON D, KAMINISKI M et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7:377–387.
   PubMed Web of Science ®Google Scholar
• BERENSON JR, LIECHTENSTEIN A, PORTER L et al.: Efficacy of pamidronate in reducing skeletal event in-patients with advanced multiple myeloma. N Engl. J. Med. (1996) 334: 488–493.
   PubMed Web of Science ®Google Scholar
• •Landmark article demonstrating reduction of skeletal morbidity with pamidronate in multiple myeloma.
   Google Scholar
• BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Long- term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. ?Clin. Oncol (1998) 16:593–602.
   Web of Science ®Google Scholar
• BERENSON JR, HILLNER BE, KYLE RAet al.: American Society of Clinical Oncology Practice Guidelines: the role of bisphosphonates in multiple myeloma. ?Clin. Oncol (2002) 20: 3719–3736.
   PubMed Web of Science ®Google Scholar
• HILLNER BE, INGLE JN,BERENSON JR eta].: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. ?Clin. Oncol (2000) 18:1378–1391.
   PubMed Web of Science ®Google Scholar
• LIPTON A, SMALL E, SAAD F et al: Thenew bisphosphonate, Zometa® (zoledronic acid) decreases skeletal complications in
   Google Scholar
• Expert Op/n. Pharmacother. (2003) 4(5) both Vic and blastic lesions: a comparisonto pamidronate. Cancer Invest. (2002) 20\(Suppl. 1):44–46.
   Google Scholar
• •Provides negative results from a large, multi-centre, randomised trial of pamidronate versus placebo, in men with painful bone metastases. The complete trial results have not yet been published.
   Google Scholar
• MCCLOSKEY EV, GUEST JF, KANIS JAet al: The clinical and cost considerations of bisphophonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs (2001) 61:1253–1274.
   PubMed Web of Science ®Google Scholar
• BRUCE NJ, MCCLOSKEY EV, KANIS JA, GUEST JF: Economic impact of using clodronate in the management of patients with multiple myeloma. Br J. Hematol. (1999) 104:358–364.
   PubMed Web of Science ®Google Scholar
• BIERMANN WA, CANTOR RI, FELLIN FM, JAKOBOWSKI J, HOPKINS L, NEWBOLD RC 3rd: An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone (1991) 12:S37–S42.
   Web of Science ®Google Scholar
• BEUSTERIEN KM, HILL MC,ACKERMAN SJ, ZACKER C: The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. Support. Care Cancer (2001) 9:169–176.
   PubMed Web of Science ®Google Scholar
• DRANITSARIS G, HSU T: Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support. Care Cancer (1999) 7:271–279.
   PubMed Web of Science ®Google Scholar
• DRANITSARIS G: Pamidronate for the prevention of skeletal-related events in multiple myeloma: what does the public think it is worth? Int. J. Technol Assess. Health Care (1999) 15:108–122.
   PubMed Web of Science ®Google Scholar
• ADAMI S, SALVANGNO G, GUARRERA G et al.: Dichloromethylenediphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. UM (1985) 134:1152–1154.
   Google Scholar
• ADAMI S, MIAN M: Clodronate therapyof metastatic bone disease in patients with prostatic carcinoma. Cancer Res. (1989) 116:67–72.
   Google Scholar
• ADAMI S: Bisphosphonates in prostate carcinoma. Cancer (1997) 80\(Suppl. 8):1674–1679.
   Google Scholar
• HEIDEREICH A, HOFMANN R, ENGELMANN UH et al.: The use ofbisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. (2001)165:136–140.
   PubMed Web of Science ®Google Scholar
• STRANG P, NILSSON S,BRANDSTEDT S et al: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anti-Cancer Res. (1997) 17:4717–4721.
   PubMed Web of Science ®Google Scholar
• KYLMALA T, TAUBE T, TAMMELA TL et al: Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind, placebo controlled study in patients with prostate cancer. Br. J. Cancer (1997) 76:939–942.
   Google Scholar
• COLEMAN RE, PUROHIT OP, VINHOLES JJ etal.: High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer (199 7) 80\(Suppl. 8):1652-1660.
   Google Scholar
• LIPTON A, GLOVER D, HARVEY H et al: Pamidronate in the treatment of bone metastases: results of two dose-ranging trials in patients with breast or prostate cancer. Ann. Oncol (1994) 5\(Suppl. 7):531–535.
   Google Scholar
• JOHNSON IS: Use of bisphosphonates for the treatment of metastatic bone pain - a survey of palliative physicians in the UK. Palliat. Med. (2001) 2:141–147.
   Google Scholar
• •Documents the widespread use of bisphosphonates for pain, despite the lack of evidence from randomised trials supporting this indication.
   Google Scholar
• PELGER RCM, HAMDY NAT, ZWIDERMAN AH et al.: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone (1998) 22:403–408.
   PubMed Web of Science ®Google Scholar
• SOERDJBALIE-MAIKOE V,PELGER RCN, LYCKLAMA A NIJEHOLT AAB etal.: Palliation of bone pain by the bisphosphonate olpadronate in hormone-escaped prostate adenocarcinoma metastatic to the skeleton.J. UM (2000) 163:261.
   Google Scholar
• HEIDENREICH A, VON KNOBLOCH R, ELERT A, HOFMANN R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. (2002) 5:1–5.
   Web of Science ®Google Scholar
• •Provides new results on the third-generation ibandronate for palliation of pain.
   Google Scholar
• LEE MV, FONG EM, SINGER FR, GUENETTE RS: Bisphosphonate treatment inhibits the growth of prostatecancer cells. Cancer Res. (2001) 61:2602–2608.
   PubMed Web of Science ®Google Scholar
• •Provides evidence for the cytotoxic activity of bisphosphonates, supporting their expanded role in both prevention and progression of prostate cancer metastases.
   Google Scholar
• CLEZARDIN P. GLIGOROV J,DELMAS P et al: Mechanisms of action of bisphosphonates on tumor cells and prospects for use in treatment of malignant osteolysis. Joint Bone Spine (2000) 67:22–29.
   PubMed Web of Science ®Google Scholar
• BOISSIER S, MAGNETTO S, FRAPPART L et al: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.Cancer Res. (1997) 57:3890–3894.
   PubMed Web of Science ®Google Scholar
• BOSSIER S, FERRERAS M,PEYRUCHAUD 0 et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. (2000) 60:2949–2954.
   Google Scholar
• TERONEN 0, HEIKKILA P,KONTTINEN YT et al.: MMP inhibition and down regulation by bisphosphonates. Ann. NY Acad. Sci. (1999) 878:453–465.
   Google Scholar
• SUN Y, GELD OFF AA, NEWLING DW, RAO BR: Progression delay of prostate tumor skeletal metastatic effect by bisphosphonates. j UM. (1992) 148:1270–1273.
   Google Scholar
• COLEMAN RE, SEAMAN JJ: The role ofzoledronic acid in cancer clinical studies in the treatment and prevention of bone metastases. Semi]. Oncol (2001) 28\(Suppl. 6):11–16.
   Google Scholar
• •A comprehensive review of the evolving role of zoledronic acid in prostate cancer-associated bone disease.
   Google Scholar
• DIEL IJ: Bisphosphonates in the prevention of bone metastases: current evidence Semin. Oncol (2001) 28\(Suppl. 6):75–80.
   Google Scholar
• ••Excellent review of current clinical data onadjuvant bisphosphonate therapy.
   Google Scholar
• KANIS JA, POWLES TJ,PATERSON AHG et al.: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone (1996) 19:663–667.
   Google Scholar
• DIEL IJ, SOLOMAYER EF, COSTA SD et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl. J. Med. (1998) 339:357–363.
   PubMed Web of Science ®Google Scholar
• DIEL IJ, SOLOMAYER EF, BASTERT G etal.: Bisphosphonates in the prevention of 715Expert Op/n. Pharmacother. (2003) 4(5)metastases in breast cancer results of the extended follow-up study. Proc. Am. Soc.CM]. Oncol. (2000) 19:314 (Abstract).
   Google Scholar
• SAARTO T, BLOMQVIST C, VIRKKUNEN P, ELOMAA I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer: 5-year results of a randomized controlled trial.j. CM]. Oncol. (2001) 19:10–17.
   PubMed Web of Science ®Google Scholar
• •An important negative, randomised trial showing a lack of benefit of clodronate.
   Google Scholar
• DEARNALEY DP, SYDES MR: Preliminary evidences that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PRO5 trial. the MRC PRO5 collaboration. Proc. Amer Soc. Chit. Oncol. (2001) 20:174a (Abstract 693).
   Google Scholar
• •An important preliminary report of a potential role of bisphosphonate therapy in delay of progression of bone metastases using a weak, first-generation agent.
   Google Scholar
• JONES J: Bisphosphonates may be useful in treatment of bone metastases.Natl. Cancer Inst. (2001) 93:1052–1053.
   Google Scholar